Klaus Mendla, Global Head at Boehringer to speak at CNS Partnering meeting Sept 22-23, San Francisco

Top Quote Klaus D. Mendla, Head of Global Business Development and Licensing CNS at Boehringer Ingelheim, will give a featured presentation on "Sincerely, Yours - Partnering with Boehringer Ingelheim in the CNS Space" at the 4th CNS Partnering and Deal-making Conference to be held in San Francisco, CA on September 22-23, 2011 by GTC. End Quote
  • (1888PressRelease) July 16, 2011 - Klaus Mendla will outline Boehringer Ingelheim's partnering strategy in the indication areas of chronic pain, neurodegenerative diseases (core indications: AD and Parkinson's disease), and psychiatric disorders (core indications: schizophrenia and depression). Boehringer Ingelheim is interested in compounds with a novel mode of action and a sound scientific rationale for improved efficacy and/or safety/tolerability compared to current standards of care. In addition to the level of scientific and medical innovation, the overall attractiveness of a licensing candidate would clearly benefit from a combination with suitable biomarkers and predictive preclinical models. For each of the core indications for CNS Licensing, Klaus will also discuss Target Licensing Product Profiles (TLPP).

    Highlights of Klaus Mendla's presentation:
    Why does the CNS market represent an attractive investment opportunity for Pharma?
    What are the key unmet medical needs in the treatment of chronic pain, neurodegenerative diseases, and psychiatric disorders?
    What kind of partnering opportunities in the CNS space is Boehringer Ingelheim interested in?

    Klaus Mendla is Head of Global Business Development and Licensing CNS at Boehringer Ingelheim. He leads the cross-functional CNS Advisory Team responsible for global licensing activities in the therapeutic area Central Nervous System Diseases (covering projects from preclinical leads to late-stage clinical and marketed products). Since joining Boehringer Ingelheim in 1985, he has held several positions in Research and Development within the corporation. Before joining Boehringer Ingelheim's International Business Development and Licensing organization, Dr. Mendla was director of the company's Neurodegeneration Research Group.
    His current focus is on licensing projects in the area of neurodegenerative diseases (including Alzheimer's and Parkinson's disease), chronic pain, and psychiatric disorders.

    The 4th CNS Partnering and Deal-making Conference gives global biotechnology and pharmaceutical companies in the CNS industry an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations, and learn about relevant CNS Disease issues and partnerships that will affect the industry.

    This event also provides a unique venue for attendees to learn about CNS Diseases business trends, the CNS disease market, and novel technologies that shape the industry. The conference is part of the CNS Diseases World Summit, which consists of 3 tracks including the "5th Neurodegenerative Conditions Research and Development" and "Advances in Neuropsychiatric Treatment".

    The sessions for the conferences are:
    Plenary Keynote Session
    Investments and Partnerships in the CNS Space
    Addressing Regulatory and Financial Decisions for Investments and Startups
    Recent Advances in CNS Development
    Case Studies in the Clinical Space
    Strategic Direction in Neuroscience
    Current Trends and Recent Deals

    For more information, please visit www.gtcbio.com

    ###
space
space
  • FB Icon Twitter Icon In-Icon
Contact Information